Vaxcyte 

Yahoo Finance • 20 days ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 22 days ago

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte, Inc. OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevna... Full story

Yahoo Finance • 23 days ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 23 days ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 23 days ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 23 days ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 26 days ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority T... Full story

Yahoo Finance • 2 months ago

Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress a... Full story

Yahoo Finance • 2 months ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte, Inc. Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferi... Full story

Yahoo Finance • 2 months ago

Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Vaxcyte (NasdaqGS:PCVX) has completed a major public equity offering, adding fresh capital to it... Full story

Yahoo Finance • 4 months ago

What Makes Vaxcyte (PCVX) So Attractive

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with... Full story

Yahoo Finance • 4 months ago

Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial. The company is evaluating VAX-31 in t... Full story

Yahoo Finance • 4 months ago

These stocks are new additions to Mizuho’s ’Americas Top Picks’ list

Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts. The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says,... Full story

Yahoo Finance • 5 months ago

IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors

IMU Biosciences PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos P... Full story

Yahoo Finance • 5 months ago

Medicxi Announces €500 Million Fund V

New fund will continue Medicxi's successful asset-centric company creation and investment strategy. LONDON, Nov. 14, 2025 /PRNewswire/ -- Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medic... Full story

Yahoo Finance • 5 months ago

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31... Full story

Yahoo Finance • 6 months ago

HAL Crosses Above Key Moving Average Level

In trading on Friday, shares of Halliburton Company (Symbol: HAL) crossed above their 200 day moving average of $34.20, changing hands as high as $35.77 per share. Halliburton Company shares are currently trading up about 8.3% on the day.... Full story

Yahoo Finance • 6 months ago

Can Thermo Fisher (TMO) Balance Biomanufacturing Expansion and AI Ambitions to Shape Its Long-Term Edge?

Vaxcyte announced a new agreement with Thermo Fisher Scientific to provide up to US$1 billion in long-term commercial fill-finish capacity for pneumococcal conjugate vaccines at Thermo Fisher's Greenville, North Carolina facility. Thermo F... Full story

Yahoo Finance • 6 months ago

Thermo Fisher (TMO) Stock Trades Up, Here Is Why

What Happened? Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 9% in the afternoon session after the company secured a major manufacturing agreement with biotechnology firm Vaxcyte and announced a new AI-focused partnershi... Full story

Yahoo Finance • 7 months ago

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to R... Full story